Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane - PubMed (original) (raw)

Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane

D T Fearon. Proc Natl Acad Sci U S A. 1979 Nov.

Abstract

An activity that is inhibitory to the properdin-stabilized amplification C3 convertase (C3b,Bb,P) was solubilized from human erythrocyte (E(hu)) membranes by Nonidet P-40 and purified to homogeneity. The inhibitory membrane glycoprotein had an apparent M(r) of 1-1.2x10(6) on gel filtration in the presence of Nonidet P-40. On sodium dodecyl sulfate/polyacrylamide gel electrophoresis it presented a single stained band with an apparent M(r) of 205,000, with or without prior reduction of disulfides. The inhibitory protein of the E(hu) membrane produced a dose-related, first-order decay of C3b,Bb,P function on sheep erythrocytes (E(s)) and released (125)I-labeled Bb from these sites, indicating a mechanism of inhibition by decay-dissociation of the amplification C3 convertase. The 50% inhibitory dose of the E(hu) membrane protein was not altered by removal of sialic acid from the E(s) bearing C3b,Bb,P sites. E(hu) membrane protein also serves as a cofactor for C3b inactivator-induced cleavage of the alpha polypeptide chain of C3b. Thus, the inhibitory membrane protein can abrogate the activity of amplification convertase sites that have formed and also can prevent generation of such sites by augmenting irreversible inactivation of C3b.Discrimination between cells by the alternative complement pathway occurs after initial deposition of C3b and is related to the modulation by surface constituents of the capacity of bound C3b to function as a subunit of the amplification C3 convertase. The existence in the E(hu) membrane of a protein that can impair the functions of membrane-bound C3b and C3b,Bb,P could represent a molecular basis for preventing inappropriate self-recognition.

PubMed Disclaimer

Similar articles

• Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
  Fearon DT. Fearon DT. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971-5. doi: 10.1073/pnas.75.4.1971. Proc Natl Acad Sci U S A. 1978. PMID: 273923 Free PMC article.
• Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
  Medof ME, Kinoshita T, Nussenzweig V. Medof ME, et al. J Exp Med. 1984 Nov 1;160(5):1558-78. doi: 10.1084/jem.160.5.1558. J Exp Med. 1984. PMID: 6238120 Free PMC article.
• Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.
  Maillet F, Kazatchkine MD, Glotz D, Fischer E, Rowe M. Maillet F, et al. Mol Immunol. 1983 Dec;20(12):1401-4. doi: 10.1016/0161-5890(83)90172-4. Mol Immunol. 1983. PMID: 6558419
• A molecular basis of activation of the alternative pathway of human complement.
  Austen KF, Fearon DT. Austen KF, et al. Adv Exp Med Biol. 1979;120B:3-17. Adv Exp Med Biol. 1979. PMID: 390986 Review.
• Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
  Fearon DT, Daha MR, Strom TB, Weiler JM, Carpenter CB, Austen KF. Fearon DT, et al. Transplant Proc. 1977 Mar;9(1):729-39. Transplant Proc. 1977. PMID: 325806 Review.

Cited by

• Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease.
  Małecka A, Østlie I, Trøen G, Małecki J, Delabie J, Tierens A, Munthe LA, Berentsen S, Tjønnfjord GE. Małecka A, et al. Clin Exp Immunol. 2024 Mar 12;216(1):45-54. doi: 10.1093/cei/uxad135. Clin Exp Immunol. 2024. PMID: 38133636 Free PMC article.
• The Molecular Mechanisms of Complement Receptor 1-It Is Complicated.
  Hardy MP, Mansour M, Rowe T, Wymann S. Hardy MP, et al. Biomolecules. 2023 Oct 13;13(10):1522. doi: 10.3390/biom13101522. Biomolecules. 2023. PMID: 37892204 Free PMC article. Review.
• Guardians of Immunity: Advances in Primary Immunodeficiency Disorders and Management.
  Peddi NC, Vuppalapati S, Sreenivasulu H, Muppalla SK, Reddy Pulliahgaru A. Peddi NC, et al. Cureus. 2023 Sep 7;15(9):e44865. doi: 10.7759/cureus.44865. eCollection 2023 Sep. Cureus. 2023. PMID: 37809154 Free PMC article. Review.
• Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.
  Schmidt CQ, Smith RJH. Schmidt CQ, et al. Immunol Rev. 2023 Jan;313(1):376-401. doi: 10.1111/imr.13164. Epub 2022 Nov 18. Immunol Rev. 2023. PMID: 36398537 Free PMC article. Review.
• Recent Progress in Red Blood Cells-Derived Particles as Novel Bioinspired Drug Delivery Systems: Challenges and Strategies for Clinical Translation.
  Vincy A, Mazumder S, Amrita, Banerjee I, Hwang KC, Vankayala R. Vincy A, et al. Front Chem. 2022 Apr 27;10:905256. doi: 10.3389/fchem.2022.905256. eCollection 2022. Front Chem. 2022. PMID: 35572105 Free PMC article. Review.

References

1. 1. J Biol Chem. 1959 Aug;234(8):1971-5 - PubMed
2. 1. J Biol Chem. 1951 Nov;193(1):265-75 - PubMed
3. 1. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971-5 - PubMed
4. 1. Proc Natl Acad Sci U S A. 1978 May;75(5):2416-20 - PubMed
5. 1. J Immunol. 1979 Jan;122(1):75-81 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal